Suppr超能文献

蛋白质聚集物的免疫原性——关注与现实。

Immunogenicity of protein aggregates--concerns and realities.

机构信息

Pfizer BioTherapeutics Pharmaceutical Sciences, Chesterfield, MO 63017, USA.

出版信息

Int J Pharm. 2012 Jul 15;431(1-2):1-11. doi: 10.1016/j.ijpharm.2012.04.040. Epub 2012 Apr 21.

Abstract

Protein aggregation is one of the key challenges in the development of protein biotherapeutics. It is a critical product quality issue as well as a potential safety concern due to the increased immunogenicity potential of these aggregates. The overwhelming safety concern has led to an increased development effort and regulatory scrutiny in recent years. The main purposes of this review are to examine the literature data on the relationship between protein aggregates and immunogenicity, to highlight the linkage and existing inconsistencies/uncertainties, and to propose directions for future investigations/development.

摘要

蛋白质聚集是蛋白质生物疗法开发面临的关键挑战之一。由于这些聚集物潜在的免疫原性增加,这是一个关键的产品质量问题,也是一个潜在的安全问题。这种压倒性的安全担忧导致近年来研发工作和监管审查的增加。本篇综述的主要目的是检查文献数据中关于蛋白质聚集物和免疫原性之间的关系,突出其关联性和现有不一致/不确定性,并为未来的研究/开发提出方向。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验